142 related articles for article (PubMed ID: 22404986)
1. Developing a nanoparticle test for prostate cancer scoring.
Huo Q; Litherland SA; Sullivan S; Hallquist H; Decker DA; Rivera-Ramirez I
J Transl Med; 2012 Mar; 10():44. PubMed ID: 22404986
[TBL] [Abstract][Full Text] [Related]
2. Gold nanoparticle-enabled blood test for early stage cancer detection and risk assessment.
Zheng T; Pierre-Pierre N; Yan X; Huo Q; Almodovar AJ; Valerio F; Rivera-Ramirez I; Griffith E; Decker DD; Chen S; Zhu N
ACS Appl Mater Interfaces; 2015 Apr; 7(12):6819-27. PubMed ID: 25757512
[TBL] [Abstract][Full Text] [Related]
3. A facile nanoparticle immunoassay for cancer biomarker discovery.
Huo Q; Colon J; Cordero A; Bogdanovic J; Baker CH; Goodison S; Pensky MY
J Nanobiotechnology; 2011 May; 9():20. PubMed ID: 21605409
[TBL] [Abstract][Full Text] [Related]
4. Different interaction modes of biomolecules with citrate-capped gold nanoparticles.
Zhang S; Moustafa Y; Huo Q
ACS Appl Mater Interfaces; 2014 Dec; 6(23):21184-92. PubMed ID: 25347206
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Study of the application of gold nanoparticles for early detection of prostate cancer.
Ahmadianpour MV; Mowla J; Sotoodehnejadnematalahi F; Raheb J
Hum Antibodies; 2020; 28(3):211-219. PubMed ID: 32224531
[TBL] [Abstract][Full Text] [Related]
7. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
8. A Single-Step Gold Nanoparticle-Blood Serum Interaction Assay Reveals Humoral Immunity Development and Immune Status of Animals from Neonates to Adults.
Zheng T; Crews J; McGill JL; Dhume K; Finn C; Strutt T; McKinstry KK; Huo Q
ACS Infect Dis; 2019 Feb; 5(2):228-238. PubMed ID: 30521752
[TBL] [Abstract][Full Text] [Related]
9. Tumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer.
Smrkolj T; Gubina B; Bizjak J; Kumer K; Fabjan T; Osredkar J
Adv Clin Exp Med; 2017 Oct; 26(7):1085-1090. PubMed ID: 29211355
[TBL] [Abstract][Full Text] [Related]
10. Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer.
Johnston WL; Catton CN; Swallow CJ
BMC Urol; 2019 Jan; 19(1):4. PubMed ID: 30616540
[TBL] [Abstract][Full Text] [Related]
11. Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis.
Sinha AA; Sackrison JL; DeLeon OF; Wilson MJ; Gleason DF
Anat Rec; 1996 Aug; 245(4):652-61. PubMed ID: 8837723
[TBL] [Abstract][Full Text] [Related]
12. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
13. Revised Gleason grading system is a better predictor of indolent prostate cancer at the time of diagnosis: retrospective clinical-pathological study on matched biopsy and radical prostatectomy specimens.
Giunchi F; Brunocilla E; Borghesi M; Rizzi S; Ricci MS; Romagnoli D; Martorana G; Schiavina R; Fiorentino M
Clin Genitourin Cancer; 2014 Oct; 12(5):325-9. PubMed ID: 24583160
[TBL] [Abstract][Full Text] [Related]
14. Glycosylation status of serum immunoglobulin G in patients with prostate diseases.
Kazuno S; Furukawa J; Shinohara Y; Murayama K; Fujime M; Ueno T; Fujimura T
Cancer Med; 2016 Jun; 5(6):1137-46. PubMed ID: 26880719
[TBL] [Abstract][Full Text] [Related]
15. Blood-based biomarkers of aggressive prostate cancer.
Liong ML; Lim CR; Yang H; Chao S; Bong CW; Leong WS; Das PK; Loh CS; Lau BE; Yu CG; Ooi EJ; Nam RK; Allen PD; Steele GS; Wassmann K; Richie JP; Liew CC
PLoS One; 2012; 7(9):e45802. PubMed ID: 23071848
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
[TBL] [Abstract][Full Text] [Related]
17. Gold nano-popcorn-based targeted diagnosis, nanotherapy treatment, and in situ monitoring of photothermal therapy response of prostate cancer cells using surface-enhanced Raman spectroscopy.
Lu W; Singh AK; Khan SA; Senapati D; Yu H; Ray PC
J Am Chem Soc; 2010 Dec; 132(51):18103-14. PubMed ID: 21128627
[TBL] [Abstract][Full Text] [Related]
18. The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score.
Sinha AA; Quast BJ; Korkowski JC; Wilson MJ; Reddy PK; Ewing SL; Sloane BF; Gleason DF
Anticancer Res; 1999; 19(4B):2821-9. PubMed ID: 10652560
[TBL] [Abstract][Full Text] [Related]
19. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
20. Prostate Cancer Diagnosis in the Clinic Using an 8-Protein Biomarker Panel.
Jones AL; Dhanapala L; Baldo TA; Sharafeldin M; Krause CE; Shen M; Moghaddam S; Faria RC; Dey DK; Watson RW; Andrawis R; Lee NH; Rusling JF
Anal Chem; 2021 Jan; 93(2):1059-1067. PubMed ID: 33289381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
